BCL-2 family inhibitors are pharmaceuticals studied in the treatment of cancer, fibrotic, and autoimmune diseases with the approach of strengthening the intrinsic apoptotic pathway by targeting anti-apoptotic proteins [7, 8]. Here, BCL2 is linked to cancer.